Qiming Venture Partners

Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.

Iongen Therepeutics is an innovative drug research and development company focusing on pain treatment.

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programs for various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.

Leyden Labs is focused on developing intranasal products that aim to protect individuals from respiratory viruses, including those in the influenza and coronavirus families. The company's innovative approach targets common characteristics across various viral families, allowing for simultaneous protection against multiple viruses rather than just specific variants, as is the case with traditional vaccines. This strategy seeks to empower individuals to safeguard themselves from infections and reduce the transmission of these diseases. Leyden Labs is driven by a team of experienced biotechnology professionals who are committed to advancing solutions that alleviate the impact of respiratory viruses on public health.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

Tianhu Technology provides drug research and development services through independent collaborative closed-loop iterations, deeply integrating AI solutions with the drug development and production process. Tianhu Technology is an innovative drug R&D company that offers high-throughput phenotypic screening and physical computing technology, as well as AI solutions that are deeply integrated into the drug R&D process.

Matwings Technology is a biotechnology company that specializes in the design of functionally optimized proteins using advanced evolutionary methods. It focuses on the development of innovative drug molecular design through computational chemistry and artificial intelligence. Matwings collaborates with major pharmaceutical companies to conduct early-stage research and development of drugs targeting complex clinical challenges. The company's goal is to achieve breakthroughs in drug targets that are typically difficult to formulate, emphasizing the clinical value of its innovations.

Tachem is a biotechnology company that specializes in the research, development, production, and distribution of products from the protected amino acid series.

Hope Medicine is committed to researching, developing and commercializing the first innovative drugs aimed at improving the quality of life for a wide range of popular male and female diseases.

Longbio Pharma is a biotechnology company focused on developing treatments for patients with complement and allergy diseases, particularly in the autoimmune sector. The company aims to provide affordable and high-quality biomedicines to both domestic and international markets. By leveraging its innovative platform, Longbio Pharma seeks to enhance treatment options for healthcare professionals, ultimately improving patient outcomes in the field of allergy and complement-related illnesses.

Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.

SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.

Simaixu Biotechnology is a biopharmaceutical firm that develop small molecule drugs for cancer, and chronic diseases with new technologies

Novamab is engaged in the research and development of innovative nanobody pharmaceuticals aimed at improving treatment options in the pharmaceutical industry. With a team experienced in nanobody research, the company has developed multiple specialized platforms, including an inhaled macromolecular drug platform, an albumin nanobody long-acting platform, and a nanobody double-antibody platform. These innovations leverage the unique advantages of nanobodies to create novel drug delivery methods, such as sprays and eye drops, addressing significant challenges in the management of chronic diseases. Novamab's research focuses on critical medical areas, including tumors, autoimmune disorders, and cardiovascular diseases, ultimately enabling healthcare professionals to enhance patient outcomes.

Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.

Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.

Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.

GenEditBio is a biotechnology company that focuses on developing gene editing drugs to address unmet medical needs associated with genetic diseases. The company specializes in innovative research and the advancement of in vivo gene editing tools, along with related delivery systems. By providing curative solutions, GenEditBio aims to improve treatment options for patients suffering from genetic disorders.

Pinnacle Medicines is a peptide drug discovery company located in Doylestown, Pennsylvania. The company specializes in developing peptide-based therapeutics to address unmet medical needs. Utilizing AI-driven drug design tools, Pinnacle Medicines focuses on creating safe and effective treatments for medical applications. Through its innovative approach, the company aims to enhance the availability of convenient and reliable therapeutics for various health challenges.

Hope Medicine is committed to researching, developing and commercializing the first innovative drugs aimed at improving the quality of life for a wide range of popular male and female diseases.

Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.

Magair Chemical is a chemical synthesis CRO that was founded by Magera Technology. It is committed to using automated and intelligent platforms to provide new drug R&D customers with a new generation of chemical synthesis CRO services, significantly shortening the delivery of chemical synthesis links in the new drug R&D cycle, and significantly reducing the costs associated with chemical synthesis, removing pharmaceutical synthesis's current reliance on manual operations.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

Tachem is a biotechnology company that specializes in the research, development, production, and distribution of products from the protected amino acid series.

Tourmaline Bio is a late-stage clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients with immune diseases. Its primary product candidate, TOUR006, is a fully human monoclonal antibody that targets interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The company leverages over twenty years of clinical and commercial experience associated with the anti-IL-6 and anti-IL-6 receptor antibody class, which has effectively treated over a million patients suffering from a range of autoimmune conditions. Tourmaline Bio is committed to addressing the needs of individuals with life-altering immune diseases through its innovative therapeutic approaches.

AskGene Pharma is a biotechnology company focused on developing innovative cytokine prodrugs to meet critical unmet medical needs in oncology and autoimmune diseases. The firm utilizes its advanced smart kine prodrug platform to fully harness the therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapies. This platform is designed to avoid systemic pharmacokinetic sinks and modulate specific immune cells within the tumor microenvironment, thereby improving safety and efficacy. By leveraging cutting-edge research and development facilities, AskGene Pharma aims to deliver next-generation therapies that offer safer and more effective treatment options for patients.

Puanita is a pet medicine brand seeking development with science and technology for pets. Puanita is headquartered in China.

BayOmics is a biotechnology company specializing in the commercial development of proteomics research. It focuses on the application of advanced biological and pharmaceutical technologies aimed at addressing critical illnesses. Utilizing integrated automated proteomics technology, BayOmics conducts functional proteome analyses and engages in the discovery of new drug targets. The company also supports targeted drug research and development based on micro-clinical samples. Through these efforts, BayOmics provides essential technical support to the medical industry, contributing to the advancement of treatments for cancer and other significant diseases.

Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.

CuroVax researches and focuses on developing and producing vaccines for various diseases. It provides biotechnology and microbiology services to improve the health and medical industry. CuroVax was founded in 2011 and is based in Changzhou City, China.

Satellos Bioscience is a private regenerative medicine company dedicated to developing innovative therapeutics aimed at stimulating or restoring muscle regeneration, particularly in severe disorders. The company's primary focus is on creating an oral therapeutic drug for Duchenne muscular dystrophy, targeting the dysregulation that is recognized as a fundamental cause of the disease's progressive characteristics. Through its research and development efforts, Satellos aims to address significant unmet medical needs within the field of muscle-related conditions.

Complete Omics is a developer focused on multi-omics diagnostics aimed at the early detection of diseases, particularly cancer. The company specializes in personalized diagnosis and treatment, leveraging patented technologies across various omics fields. By offering precision companion diagnostics, Complete Omics enables researchers and pharmaceutical companies to conduct highly sensitive and specific health surveillance tests, facilitating improved patient outcomes through tailored medical interventions.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company employs a precision oncology platform that utilizes purpose-built vectors to deliver high-energy radio-isotopes directly to tumors and metastatic lesions. This innovative approach to targeted radiotherapy aims to improve treatment efficacy for patients with challenging cancer diagnoses. Abdera's work in this emerging field aligns with a significant market potential, as targeted alpha therapies are expected to play a major role in the future of nuclear medicine.

Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.

Puanita is a pet medicine brand seeking development with science and technology for pets. Puanita is headquartered in China.

Caidya is a clinical research organization based in North Carolina, founded in 2021. It specializes in providing personalized solutions across various therapeutic areas and aims to enhance the efficiency of clinical trials. Caidya develops a proprietary technology platform that integrates data from multiple systems, offering a near real-time overview of clinical trials. The organization also offers advisory services focused on clinical development plans, regulatory strategies, and approval processes, which support bio-pharmaceutical and medical companies in optimizing their clinical development capabilities. By facilitating the globalization of innovative drugs, Caidya seeks to accelerate the development of medicines and improve the overall success rates of clinical trials.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.

OriCell Therapeutics develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.

Bio-Link is a drug development company established in 2001 and headquartered in Shanghai, China. It specializes in providing bioprocessing solutions for the life science industry, focusing on the development and manufacturing of essential process equipment and consumables. These products are utilized in the production of vaccines, antibody drugs, cell therapy, gene therapy, and other biologics. Bio-Link's offerings encompass upstream cell culture, disposable dispensing reservoirs, downstream chromatography, ultrafiltration, and filtration, along with process development services. The company aims to deliver high-quality and innovative solutions that enhance the efficiency, safety, and competitiveness of the biopharmaceutical supply chain. Additionally, there are indications that Bio-Link may explore wearable technology aimed at elderly care.

BayOmics is a biotechnology company specializing in the commercial development of proteomics research. It focuses on the application of advanced biological and pharmaceutical technologies aimed at addressing critical illnesses. Utilizing integrated automated proteomics technology, BayOmics conducts functional proteome analyses and engages in the discovery of new drug targets. The company also supports targeted drug research and development based on micro-clinical samples. Through these efforts, BayOmics provides essential technical support to the medical industry, contributing to the advancement of treatments for cancer and other significant diseases.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

OriCell Therapeutics develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments. OriginCell was founded in 2014 and is headquartered in Shanghai, China.

Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development of innovative therapeutics to address unmet medical need, especially in the area of respiratory viral infection and viral hepatitis, for global and China market. We strive to build a science-driven biopharmaceutical company that aims to be a leader in antiviral drug discovery and development. To achieve so, we aspire for the excellence of science and be innovative. We operate with a razor-sharp focus and aggressiveness with a timely and cost efficient manner. We create a healthy and rewarding work environment for employees, and seek a superior rate of return for investors and partners.

Puanita is a pet medicine brand seeking development with science and technology for pets. Puanita is headquartered in China.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

AskGene Pharma is a biotechnology company focused on developing innovative cytokine prodrugs to meet critical unmet medical needs in oncology and autoimmune diseases. The firm utilizes its advanced smart kine prodrug platform to fully harness the therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapies. This platform is designed to avoid systemic pharmacokinetic sinks and modulate specific immune cells within the tumor microenvironment, thereby improving safety and efficacy. By leveraging cutting-edge research and development facilities, AskGene Pharma aims to deliver next-generation therapies that offer safer and more effective treatment options for patients.

Ashermed is a provider of contract research organization (CRO) services specifically designed for medical companies. The company emphasizes the integration of advanced technologies, such as Internet technology, big data, and artificial intelligence, to enhance the drug development process. By leveraging these technologies, Ashermed aims to shorten the clinical data development cycle and improve the quality of research outcomes, ultimately reducing research and development costs for its clients. Their offerings include CRO services, site management organization (SMO) support, patient recruitment, and digital platform assistance, all tailored to facilitate the needs of the medical industry.

Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.

Ceptur Therapeutics is focused on developing innovative genetic medicines aimed at addressing diseases that currently lack effective treatments. The company utilizes its proprietary U1 Adaptor technology, which enables long-lasting and non-genotoxic silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and holds promise for cancer treatment, allowing healthcare providers to offer new therapeutic options for patients with various types of cancers.

Zhenge Biotech is a macromolecular pharmaceutical contract development and manufacturing organisation.

Korro Bio Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing nucleic acid-based therapeutics aimed at editing RNA to treat rare and prevalent diseases. Founded in 2018, the company has created a proprietary platform that allows for efficient and selective RNA editing, leveraging natural processes found in multicellular organisms. This innovative approach enables precise modifications to messenger RNA, allowing for targeted changes in protein structure and function across various tissues. By focusing on RNA instead of DNA, Korro Bio aims to enhance the precision and adaptability of genetic medicines, expanding their potential applications in treating a range of medical conditions.

Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.

DP Technology is a global leader in the "AI for Science" research paradigm, where AI learns scientific principles and data, then tackles key challenges in scientific research and industrial R&D. DP's commitment to interdisciplinary research has led to the creation of the DP "Particle Universe", an array of pre-trained large science models designed to bridge foundational research with practical industrial applications. DP's software suite includes the Bohrium® Scientific Research Space, Hermite® Computational Drug Design Platform, RiDYMO® Dynamics Platform, and Piloteye® Battery Design Automation Platform. Together, these platforms form a robust foundation for industrial innovation and an open ecosystem for AI in science, fostering advancements in key areas such as drug discovery, energy, material science, and information technology.

Clinflash is a leading provider of cloud-based solution and relevant professional service in filed of clinical development in China. Clinflash aims to help pharmaceutical companies improve R&D effectiveness and efficiency through providing first class IT solution and professional service.

Sinogen Biopharma is founded with a vision to bridge China's biotech innovation to the US pharma market. The company licenses and develops innovative drugs from China.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.

Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), food additives, biologics，pesticides，veterinary drugs, and new cosmetics.

Okeanos offers a custom synthesis and production of special chemical biological reagents and pharmaceutical intermediates for life sciences. The company's main products are modified nucleotides, unnatural amino acids, heterocycle, and fluorescent and labeling reagents. Okeanos offers chemical compounds, pharmaceutical intermediates to the world-famous pharmaceutical companies, such as Pfizer, P&G Novartis, etc and enjoys a good reputation from the customers.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Genevide is a biotech company that specializes in gene research and development. Genevide was founded in 2019 and is located in Suzhou, Jiangsu, China.

HilleVax is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a virus-like particle (VLP) based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HilleVax is dedicated to addressing significant public health challenges through its vaccine initiatives.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Neuro3 Therapeutics is a Hong Kong based company that advances medicines for CNS diseases.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Hope Medicine is committed to researching, developing and commercializing the first innovative drugs aimed at improving the quality of life for a wide range of popular male and female diseases.

Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.

SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Zhenge Biotech is a macromolecular pharmaceutical contract development and manufacturing organisation.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.

OriCell Therapeutics develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. It specializes in developing complement-targeted therapies aimed at treating immune-mediated diseases. The company focuses on pioneering drug discovery related to the complement system, with the goal of providing transformative therapies for individuals suffering from complement-mediated conditions.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. It specializes in developing complement-targeted therapies aimed at treating immune-mediated diseases. The company focuses on pioneering drug discovery related to the complement system, with the goal of providing transformative therapies for individuals suffering from complement-mediated conditions.

Asieris Pharmaceuticals Co. Ltd. is a Chinese biotechnology company established in 2010, headquartered in Taizhou, China. The company specializes in the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. Asieris is committed to advancing therapeutic solutions that integrate both diagnosis and treatment, catering to the needs of patients in China and globally. Through its innovative approach, the company seeks to contribute significantly to the fields of oncology and infectious disease management.

MEDx provides precision medicine solutions to improve clinical development. Its services use translational science for diagnostic technology of nucleic acid and protein. It also offers biomarker development, Companion Diagnostics (CDx), Point-of-Care (POC) development, clinical testing, and commercialization. The company was founded in 2013 and is headquartered in Suzhou, Jiangsu.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company specializes in targeted therapies, particularly for lung cancer, breast cancer, and gout. Its product pipeline includes small molecule drug candidates, such as D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in developing novel immuno-oncology therapies that can be used in conjunction with existing treatments like PD-1 antibodies for various cancer types. The company was co-founded by Dr. Yaolin Wang and other scientists with extensive experience in drug discovery at leading pharmaceutical firms, focusing on significant health challenges such as tumors and metabolic disorders.

Korro Bio Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing nucleic acid-based therapeutics aimed at editing RNA to treat rare and prevalent diseases. Founded in 2018, the company has created a proprietary platform that allows for efficient and selective RNA editing, leveraging natural processes found in multicellular organisms. This innovative approach enables precise modifications to messenger RNA, allowing for targeted changes in protein structure and function across various tissues. By focusing on RNA instead of DNA, Korro Bio aims to enhance the precision and adaptability of genetic medicines, expanding their potential applications in treating a range of medical conditions.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.

New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.

OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments. OriginCell was founded in 2014 and is headquartered in Shanghai, China.